Biotech and healthcare stocks continue to respond sharply to progress in clinical trials, regulatory developments, and broader economic indicators. With the Federal Reserve initiating its first rate cut of 2025 and signaling a more accommodative stance, capital-intensive sectors such as biotechnology are likely to benefit from improved funding conditions and renewed market interest. Against this backdrop, several companies have seen notable price movement after hours, driven by pipeline progress, financing ...